

ESACT-UK 24th Annual Scientific Meeting Programme

Wednesday 8th January 2014

- 10:45-11:00** **Meeting introduction**
Jon Dempsey; ESACT-UK committee chair
- 11:00-11:45** **Keynote Speaker**
Genome scale science for CHO
Nicole Borth; BOKU, Austria
- 11:45-12:00** **BioProNET**
- 12:00-13:00** *Lunch and Careers opportunities forum*
- 13:00-14:30** **Session 1 – Upstream Processing**
Recombination-mediated cassette exchange (RMCE) for monoclonal antibody expression in a CHOK1SV-derived host cell line
Robert Young; Lonza
- CHO cell line specific prediction and control of recombinant monoclonal antibody N-glycosylation**
Rhian Grainger; University of Sheffield
- TBC**
TBC; MedImmune
- 14:30-15:00* *Tea/coffee, trade stands and poster viewing*
- 15:00-16:30** **Session 2 – Downstream Processing and Formulation**
TBC
TBC; Eden
- Protein separations in extruded microfluidics**
Nuno Reis, Loughborough
- TBC**
TBC; Arecor
- 16:30-17:00* *Tea/coffee and trade stand viewing*
- 17:00-18:00** **Session 3 – Early Career Researchers**
Talks to be selected from submitted abstracts
- 18:00-18:15** **Update on ESACT-UK activities**
Jon Dempsey; ESACT-UK committee chair
- 18:15-20:00** Posters, trade stand viewing and networking
- 20:00** *ESACT-UK society dinner and after-dinner quiz*

Thursday 9th January 2014

07:30-08:30

Breakfast

09:00-10:30

Session 4 – New Technologies

Non-invasive, label-free, quantitative characterisation of live cells in monolayer culture

Melissa Mather; University of Nottingham

Applications of genome editing technologies in tackling disease: from target discovery to drug manufacture

Holly Astley; Horizon Discovery

TBC

TBC

10:30-11:00

Tea/coffee and trade stand viewing

11:00-12:30

Session 5 – Stem cells and tissue engineering

Bioreactors for cell therapy scale up

Marianne Ellis; University of Bath

Metabo-lungTM: a working model of human lung tissue to test toxicity of drugs

Kelly BeruBe; Cardiff University

3D scaffolds and in vitro models for nerve tissue

John Haycock; University of Sheffield

12:30-13:30

Lunch

13:30-14:15

Keynote Speaker

Biopharmaceutical Critical Quality Attributes: Where are we and where do we want to be?

Mark Uden; GSK

14:15-15:45

Session 6 – Novel therapeutics

Novel molecules capabilities at MedImmune

Chris Lloyd; MedImmune

The BEAT platform: innovative solutions for the industrial production of bispecific antibodies

Pierre Moretti, Glenmark Pharmaceuticals

Chemically labile linker technologies provide improved stability profiles in ADC development

David Simpson; Glythera

15:45-16:00

Award of prizes and close of meeting